Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34276662/
doi: 10.3389/fimmu.2021.673636. 1 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, The First Affiliated Hospital of Soochow...
Hypoxemic respiratory failure following ruxolitinib discontinuation in allogeneic hematopoietic cell transplantation recipients - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34272781/
Ruxolitinib, a selective inhibitor of Janus kinases 1 and 2, is increasingly being used in allogeneic hematopoietic cell transplantation (HCT) recipients, following its approval by the US Food and Drug...
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34260836/
Among patients with glucocorticoid-refractory or -dependent chronic GVHD, ruxolitinib led to significantly greater overall response, failure-free survival, and symptom response. The incidence of thrombocytopenia and anemia was greater with ruxolitinib....
-
Naveed Saleh, MD, MS – Skipta Team5yrKey Points • Conclusion/Relevance: “Among patients with glucocorticoid-refractory or -dependent chronic GVHD, ruxolitinib led to significantly greater overall response, failure-free survival, and symptom response. The incidence of thrombocytopenia and anemia was Show More
Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34184542/
Aim: Graft-versus-host disease (GvHD) is a major complication arising in patients undergoing allogenic hematopoietic stem cell transplantation. Material & methods: We tested ruxolitinib (a selective JAK1/2 inhibitor) efficacy in three...
Biomarker profile predicts clinical efficacy of extracorporeal photopheresis in steroid-resistant acute and chronic graft-vs-host disease after allogenic hematopoietic stem cell transplant - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34185332/
We conducted a multicenter interventional study to assess the efficacy of Therakos ECP to treat steroid-resistant graft-vs-host disease (SRes-GVHD) after allogeneic HSCT and to identify biomarkers of GVHD response. A...